PreTT

PreTT is revolutionizing cancer treatment with its pioneering work in best-in-class pretargeted radioligand therapies, surpassing the capabilities of traditional methods. With an exclusive pretargeting technology, PreTT is poised to transform radioimmunotherapies using monoclonal antibodies (mAbs), making a significant impact in the fight against cancer. Located in København, DK, PreTT is dedicated to advancing the future of cancer therapeutics through innovative solutions and cutting-edge research.

PreTT is committed to developing and delivering innovative healthcare solutions that improve patient outcomes and quality of life. By focusing on the development of advanced radioligand therapies, PreTT aims to provide more effective and targeted cancer treatments. The company's dedication to innovation and excellence drives its mission to revolutionize the healthcare industry and make a meaningful difference in the lives of patients worldwide.

PreTT continues to expand its reach and impact in the pharmaceutical landscape, striving to make its pretargeted radioligand therapies accessible to patients in need. The company operates out of København, DK, and is focused on forging partnerships and collaborations to accelerate the development and commercialization of its groundbreaking technologies. We invite the manager of PreTT to create a customized and exclusive company showcase and product listing on our platform.